Sudeep Pharma Limited IPO

Mainboard

Offer Date: Nov 21, 2025 - Nov 25, 2025

₹ 14825 /25 Shares

21 Nov, 2025

Open Date

25 Nov, 2025

Close Date

26 Nov, 2025

Allotment Date

28 Nov, 2025

Listing Date

Expected Premium

+ ₹85-90 (14.33%)

*Expected Premium provided in this app is derived from market rumors. It is not a guaranteed indicator of the actual listing price and should be interpreted with caution.

Expected Premium

+ ₹85-90 (14.33%)

Sudeep Pharma IPO Issue Details

Issue Price ₹563-593 per equity share
Face Value ₹1 Per Equity Share
Total Issue Size 1,50,92,750 shares(aggregating up to ₹895 crore)
Fresh Share 16,02,024 shares(aggregating up to ₹95 crore)
Offer For Sale 1,34,90,726 shares(aggregating up to ₹800 crore)
Listing at BSE, NSE
Lead Manager ICICI Securities Ltd.
IIFL Capital Services Ltd.
Registrar MUFG Intime India Pvt Ltd

Market Lot Size

Investors can bid for a minimum of 25 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.

Application	Lots	Shares	Amount
Retail (min)	1	25	₹14,825
Retail(max)	13	325	₹1,92,725
SHNI(min)	14	350	₹2,07,550
SHNI(max)	67	1,675	₹9,93,275
BHNI(min)	68	1,700	₹10,08,100

Sudeep Pharma IPO Documents

DRHP

RHP

Sudeep Pharma IPO Details

Sudeep Pharma IPO is a book-built issue of ₹895 crores, The total issue size is ₹895 crores. The IPO of Sudeep Pharma is priced at ₹563-593 per equity share, which has a face value of ₹1 Per Equity Share each, IPO bidding starts from Nov 21, 2025 and ends on Nov 25, 2025. The allotment for Sudeep Pharma IPO will be finalized on Nov 26, 2025. Sudeep Pharma IPO will be listed on BSE, NSE, with a tentative listing date fixed as Nov 28, 2025. The company shall list its equity shares on the BSE, NSE. MUFG Intime India Pvt Ltd is the registrar of the issue.

Retail investors can bid for a minimum of 25 shares, extendable to 14,825. S-HNIs will be able to bid for 350 shares at ₹2,07,550, while B-HNIs can also apply for a bid of 1,700 shares at ₹10,08,100. The book-running lead manager for the IPO is/are ICICI Securities Ltd., IIFL Capital Services Ltd..

The total issue ₹895 crore, comprising a fresh issue of 16,02,024 shares ₹95 crore and having Offer for Sale (OFS) of 1,34,90,726 shares to mop up ₹800 crore.

The Sudeep Pharma IPO sets its price band at 563-593 for each share. A single application for Sudeep Pharma Limited IPO must contain at least 25 shares. Sentiment investors need to invest a minimum of 25 through their retail account. For investors to prevent oversubscription issues, they should submit bids at the cutoff price, which estimates about ₹14,825 In order to participate in the sNII, investors must purchase at least 14 lots of 350 shares for ₹2,07,550, while the bNII requires 68 lots of 1,700 shares for an investment of ₹10,08,100.

Sudeep Pharma Valuations

EPS Pre IPO ₹12.46/-

EPS Post IPO ₹11.07/-

P/E Pre IPO 47.61

P/E Post IPO 53.55

Debt/Equity 0.20

RoNW 27.88%

PAT Margin 27.63%

Price to Book Value 12.93

Market Cap. 6697.85 Cr.

Sudeep Pharma Company Financials

In Crs.

In Cr.

	30-Jun-25	31-Mar-25	31-Mar-24	31-Mar-23
Assets	922.26	717.17	513.87	420.11
Revenue	130.08	511.33	465.38	438.26
Profit After Tax	31.27	138.69	133.15	62.32
Net Worth	688.32	497.53	359.07	226.29
Reserves & Surplus	668.52	481.11	354.59	221.88
Total Borrowing	135.97	135.25	75.03	82.26

About Sudeep Pharma Company

Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.It has six manufacturing facilities that have a combined production capacity of 50,000 MT, manufacturing minerals such as calcium, iron, magnesium, zinc, potassium, and sodium.

The company supplies over 200 products to a wide customer base across the pharma, food, and nutrition sectors.The company has strong R&D capabilities comprising in-house labs and pilot-scale facilities for mineral salts and excipients.

Product Portfolio:
Pharmaceutical, Food and Nutrition Business
Specialty Ingredients Business

Triturates As of 31 December 2024, the company had 704 permanent employees.

Sudeep Pharma - Promoter(s)

Sujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani HUF, Riva Resources Private Limited, and Bhayani Family Trust

Pre Issue Share Holding : 89.36%

Post Issue Share Holding : 76.15%

Sudeep Pharma IPO - Issue Objectives

Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I– ₹75.81 Cr

General corporate purposes

Strength

The diversified portfolio includes market leadership in pharmaceutical, food, nutrition, and specialty ingredients as of June 30, 2025; a strong positioning in mineral-based products; iron phosphate; a wide array of specialty food ingredients, such as encapsulated preservatives.

Robust and Compliant Manufacturing Infrastructure: The company operates four manufacturing facilities with 12 production lines across Gujarat and Ireland, covering 68,446 sq. meters and offering an annual capacity of 72,246 MT, ensuring strong compliance and efficient production capabilities.

Strong R&D Capabilities Driving Innovation: It has two R&D facilities with a committed team of 41 professionals, working on particle engineering, enhancing shelf life, nutrient bioavailability, and formulation solutions with support from advanced equipment in developing technology, improving sustainability, and ensuring product expansion.

Weakness

High Revenue Dependence on Limited Customers: A significant portion of revenue comes from a small number of customers, and the loss of any one or reduced demand could adversely affect business, financial performance, and cash flows.

Regulatory and Quality Compliance Risks: Manufacturing facilities of the company are subject to regular inspections and strict standards laid down by global agencies such as USFDA, EXCiPACT, FSSC, WHO-GMP, ISO, and HACCP. Any quality issues or non-compliance may further lead to regulatory action and reputational loss.

Operational Disruption Risks: Manufacturing and R&D operations are exposed to equipment failure, industrial accidents, regulatory non-compliance, natural disasters, and infectious disease outbreaks, among other risks. A slowdown or shutdown would adversely impact business, results, and cash flows.

Contact Details

Sudeep Pharma

129/1/A, GIDC Estate, Nandesari, Vadodara, Gujarat, 391340

+91 265 284 0656

cs.sudeep@sudeepgroup.com

https://www.sudeeppharma.com/

Registrar Contact Details

MUFG Intime India Private Limited (Link Intime)

+91-22-4918 6270

sudeeppharma.ipo@in.mpms.mufg.com

https://in.mpms.mufg.com/Initial_Offer/public-issues.html

Sudeep Pharma IPO - FAQs

Ans. Sudeep Pharma Limited IPO is a Mainboard IPO. The issue is priced at ₹563-593 per equity share. The minimum order quantity is 25 Shares. The IPO opens on Nov 21, 2025, and closes on Nov 25, 2025. MUFG Intime India Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Ans. The Sudeep Pharma Limited IPO opens on Nov 21, 2025 and closes on Nov 25, 2025.

Ans. You can track the real-time subscription numbers using the links below:

Ans. The size of Sudeep Pharma Limited IPO is Total 895.00 Cr : #Fresh Issue : 16,02,024 shares(aggregating up to ₹95.00 Cr) + #OFS : 1,34,90,726 shares of ₹1(aggregating up to ₹800.00 Cr).

Ans. The Sudeep Pharma Limited IPO price band is set between ₹563-593 per equity share.

Ans. To apply for Sudeep Pharma Limited IPO, follow the steps given below:

- Open the IPO Ji App or Website
- Find Sudeep Pharma Limited IPO in the List of IPOs
- Press Apply Button
- Select Your Demat Account
- Select Your Shares Quantity and Submit
- Track Your IPO Status

Ans. The share allotment date of Sudeep Pharma Limited IPO is Nov 26, 2025.

Ans. The Sudeep Pharma Limited IPO will be listed on Nov 28, 2025.

Ans. Follow the steps to check the Sudeep Pharma Limited IPO allotment status online.